Takeda Deal History & Licensing Activity
Takeda is a large pharma headquartered in Japan. Over the past three years, Takeda has been involved in 20 licensing and acquisition transactions, with a primary focus on Small Molecules (10 deals). The company currently has 50 active clinical trials, primarily in Autoimmune.
Deals (12mo)
2
Active Trials
50
Top Modality
Small Molecules
Focus Area
Autoimmune
Takeda Recent Deal Activity
Licensing, acquisition, and partnership transactions involving Takeda in the past 12 months.
| Asset | Partner | Modality | Phase | Type | Date |
|---|---|---|---|---|---|
| AI-designed oncology candidate | Insilico Medicine | Small Molecules | Preclinical | collaboration | Jun 15, 2026 |
| olverembatinib | Ascentage | Small Molecules | Unknown | license | May 20, 2026 |
| Gamma delta T-cell platform | GammaDelta Therapeutics | Cell Therapy | Preclinical | option |
Takeda Pipeline Focus
Therapeutic areas and modalities where Takeda is most active based on deal history and clinical trial data.
Therapeutic Areas
Takeda Strategic Signals
Key indicators of Takeda's licensing and acquisition strategy, including patent expirations, pipeline gaps, and strategic priorities.
Strategic Profile
Acquisition Appetite
Strategic Priorities
Takeda Clinical Pipeline
Takeda has 50 active clinical trials across 6 development phases.
16
Unknown
1
Not Applicable
1
Phase 4
2
Phase 1
12
Phase 2
18
Phase 3
See How Your Asset Matches Takeda's Portfolio
Use Solidus to benchmark upfront payments, milestones, and royalties for Autoimmune assets — powered by data from 3,500+ real biopharma transactions.
Related Intelligence
Oncology Deal Benchmarks
Market sizing, deal terms, and competitive landscape for oncology
Small Molecules Benchmarks
Upfront, milestone, and royalty benchmarks for small molecules deals
Peptides Benchmarks
Upfront, milestone, and royalty benchmarks for peptides deals
Deal Pulse
Track the latest biopharma licensing and acquisition deals across all therapeutic areas
All Company Profiles
Browse 850+ biotech and pharma company profiles with deal history and pipeline data
2026 Deal Benchmarks Report
About Takeda Licensing & Deal Activity
Takeda is a large pharma company based in Japan that has been actively engaged in licensing transactions across the biopharma landscape. With 20 deals over the past three years, Takeda ranks among the most acquisitive companies tracked by Ambrosia Ventures.
Key therapeutic areas of focus for Takeda include Autoimmune (15 deals and trials), Oncology (13 deals and trials), CNS Disorders (6 deals and trials), and Solid Tumors (6 deals and trials). In terms of modality, Takeda has shown particular interest in small molecules, peptides, antibodies.
Ambrosia Ventures tracks deal terms, pipeline data, patent expirations, and competitive positioning for Takeda and 850+ other biopharma companies. Use our Solidus to benchmark your asset against Takeda's historical deal terms, or explore all company profiles to find the best partner match for your pipeline.